Cosibelimab
UNLOXCYT (cosibelimab) is a monoclonal antibody that blocks PD-L1 to help the immune system fight cancer cells. It's given as an intravenous injection, with each vial containing 300 mg in 5 mL. Manufactured by Checkpoint Therapeutics, Inc., it's approved for prescription use. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | UNLOXCYT (cosibelimab) is a monoclonal antibody that blocks PD-L1 to help the immune system fight cancer cells. It's given as an intravenous injection, with each vial containing 300 mg in 5 mL. Manufactured by Checkpoint Therapeutics, Inc., it's approved for prescription use. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Cosibelimab",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Cosibelimab — ANDA 761297 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761297"
}
]
|
| identifier | ANDA761297 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"drug-manufacturers",
"health-care",
"medications",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Cosibelimab |
